$IREN Ltd(IREN)$ IREN Limited (NASDAQ: IREN) is experiencing massive momentum, closing up at $56.56 following a string of transformational AI megadeals. Following the company's Q3 earnings report, Bernstein reiterated an Outperform rating and a $100 price target, implying roughly 76% upside from early-May baseline levels. The Case for Bernstein's $100 Target: Full Pivot to AI Cloud Massive NVIDIA Deal: IREN secured a massive $3.4 billion AI cloud contract with NVIDIA, which also includes a $2.1 billion equity investment option. Hyper-Scale Revenue: The company has contracted 150,000 GPUs, with half already dedicated to a massive five-year agreement with Microsoft generating over $1.94 billion in annualized revenue. Dumping Bitcoin Min
$NIO Inc. USD OV(NIO.SI)$ $XPeng Inc.(XPEV)$ Singapore’s Category A COE is nearing the $125,000 milestone after closing at $124,790 in the latest May 2026 bidding exercise. With the upcoming The Car Expo keeping automotive demand high, mass-market buyers are being heavily squeezed. This raises a major question for automotive stocks: are global automakers in Singapore for massive profit margins, or strictly for brand prestige? The Financial Disconnect: Prestige vs. Real Profits Prestige Play: Singapore serves as a premier showcase market for Southeast Asian luxury branding. Margin Compression: Massive COE taxes heavily inflate retail costs without adding to factory profit margins.
$Rocket Lab USA, Inc.(RKLB)$ $AST SpaceMobile, Inc.(ASTS)$ #RKLB # ASTS The space sector is seeing a massive divergence today as Rocket Lab ($RKLB) hits all-time highs while AST SpaceMobile ($ASTS) faces a sharp pullback. Is this a rotation into "proven execution" or a classic "buy the dip" opportunity for the satellite leader?🚀 Rocket Lab ($RKLB): The Execution Machine$RKLB is on a tear, surging over 11% today to cross the $117 mark after a "wow" earnings report.Record Numbers: Reported record Q1 revenue of $200.3M (up 64% YoY) and a massive $2.2B backlog.Profitability Pivot: Management stunned Wall Street by guiding for positive adjusted EBITDA of $23M next quarter—a year ahead o
$Lumentum(LITE)$ #Lumentum Big move for $LITE! Effective prior to market open on May 18, 2026, Lumentum will officially join the Nasdaq-100 Index, replacing CoStar Group.This marks a massive year for the photonics leader—it just joined the S&P 500 in March—and the stock is already up over 145% year-to-date.🌪️ The "Passive Inflow" ThesisForced Buying: Passive funds and ETFs tracking the Nasdaq-100 (which manage over $600 billion) are now required to buy Lumentum shares.The AI Tailwinds: As a key supplier for 800G optical modules, Lumentum is essential to the "physical layer" of AI data centers.Price Targets: Major institutions like Citigroup and Jefferies have recently hiked targets to as high as $1,100 - $1,200.⚠️ The "Take Profit
Tencent just dropped its Q4 2025 results, posting a revenue of RMB 194.4 billion (up 13% YoY) and a net profit of RMB 58.26 billion. While the numbers beat expectations, the real buzz is around WeChat's AI-driven evolution.🚀 The AI "Monetization Point" is HereManagement's commentary suggests AI has shifted from a "research cost" to a "revenue engine" within the WeChat ecosystem:Ad Targeting Supercharge: Marketing services revenue grew 17% to RMB 41.1 billion, largely credited to AI-powered targeting. By better matching ads to user intent, Tencent is squeezing more value out of its existing ad load.The "ClawBot" Integration: Tencent is aggressively rolling out AI agents (like ClawBot) directly into WeChat. These agents aren't just for chat—they are being designed to handle multi-step tasks
The market is opening the week on a high note after the S&P 500 ($7,398.93) and NASDAQ ($26,247.08) both hit fresh record highs on Friday. However, caution is creeping in this morning as futures trade slightly lower ahead of tomorrow's critical April CPI release, with investors bracing for a potential 3.7% year-over-year headline inflation figure.🔥 Top Stocks in Focus TodayTickerCatalystWhat to WatchNVDA (Nvidia)AI Capex BoomAnalysts at Goldman Sachs see multiple catalysts ahead of its earnings call later this month; big tech AI spending is projected to hit $725 billion this year.AMAT (Applied Materials)Earnings (Thurs)Reporting later this week; options are pricing in a volatile +/- 8.7% move. The stock is already up ~12% so far in May.BABA (Alibaba)China Tech SentimentReporting Wednes
$AST SpaceMobile, Inc.(ASTS)$ The space race is heating up, and investors are comparing the "execution king" Rocket Lab ($RKLB) with the "high-reward disruptor" AST SpaceMobile ($ASTS). With both companies reporting, here is the quick breakdown of the 2026 momentum:Rocket Lab ($RKLB): The Execution Leader.Commercial Win: Just reported record Q1 2026 revenue of $200.3 million (up 63.5% YoY).Backlog: Their massive $2.2 billion backlog proves they have steady, real-world demand from both government and commercial customers.Status: Moving toward profitability with a diversified business (launches + satellite parts).AST SpaceMobile ($ASTS): The High-Growth Wildcard.Commercial Pivot: Reported $70.9 million in 2025 revenue—a huge jump from their "p
The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit
The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit